British & American Investment Trust PLC (BAF.L) is a self-managed investment trust company quoted on the London Stock Exchange that invests predominantly in other investment trusts and leading United Kingdom- and United States-quoted companies to achieve a balance of income and growth; its portfolio includes holdings such as Geron Corporation, Lineage Cell Therapeutics, Aberdeen Diversified Income & Growth, Dunedin Income Growth, ADVFN, Relief Therapeutics, and Audioboom across sectors including biotechnology, biomedical, healthcare, media, semiconductors, and telecommunications. Founded in 1947 and headquartered at Wessex House, 1 Chesham Street, London SW1X 8ND, United Kingdom, the company operates primarily in global equity income markets with a focus on public equity investments in the UK and US, maintaining total assets of approximately £4m, 25 million shares in issue, and a semi-annual dividend frequency yielding around 10.94% as of recent data. Recent developments include the publication of its annual financial report in April 2025, half-year report in September 2024, and Net Asset Value announcements through August 2025 alongside its AGM on 26 June 2025, with no major acquisitions, funding rounds, or strategic shifts reported in the past 1-2 years.